Navigation Links
JPM-TMT Awards New Contract to Study Administration using Marburg Virus Drug
Date:9/6/2012

FORT BELVOIR, Va., Sept. 6, 2012 /PRNewswire-USNewswire/ -- A contract to evaluate an alternative method for delivering a medical countermeasure (MCM) was awarded to Sarepta Therapeutics by the Joint Project Manager Transformational Medical Technologies (JPM-TMT).  A component of the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD), JPM-TMT has made significant progress in the development of a therapeutic to fight the highly lethal Marburg virus.  During the course of developing the drug candidate thus far, the intravenous (IV) method of delivery is being utilized.  This new $3.9 million contract will evaluate the feasibility of an intramuscular (IM) route, a more practical administration of a drug.

(Logo: http://photos.prnewswire.com/prnh/20120315/DC71198LOGO)

John Anderson, Product Manager of JPM-TMT's Hemorrhagic Fever Virus-Therapeutics Medical Countermeasures acquisition program, commented on the development of the drug candidate. "With AVI-7288 showing survival rates up to four days post infection, we are eager to determine whether it is feasible to deliver a drug intramuscularly—a route that could reduce the logistical burden of administering the medical countermeasure to our Warfighter. IM delivery is both easier and quicker to administer.  The IV route takes up to one hour while IM administration takes just seconds. The potential for efficient treatment in a mass casualty situation is obvious."

There is no treatment for infection caused by Marburg virus, a member of the Filoviridae family of Hemorrhagic Fever Viruses (HFV).  The disease is characterized by high fever, chills, nausea, vomiting, chest pain, diarrhea, and in some cases, massive hemorrhaging and organ dysfunction. 

"Developing a treatment for the highly lethal Marburg virus infection is ground-breaking," said David E. Hough, Joint Project Manager for JPM-TMT. "JPM-TMT is the only U.S. government agency testing a post-exposure drug candidate against this dangerous disease. Our goal is to successfully develop a therapeutic for the Marburg virus infection using platform technologies that will ultimately have the capacity to rapidly respond to outbreaks of all HFVs as well as other biological pathogens. Both our Warfighters and the nation stand to benefit from our unique approach."

Joint Project Manager Transformational Medical Technologies (JPM-TMT)

JPM-TMT is a component of the U.S. Department of Defense's Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD). JPM-TMT aims to protect the Warfighter from emerging infectious diseases, genetically altered, and unknown biological threats. Through strategic investments and partnerships with innovative biotech firms, pharmaceutical corporations, other government agencies, and academic institutions, JPM-TMT facilitates the advanced development and acquisition of adaptable platform technologies, broad-spectrum medical countermeasures, and innovative systems to enhance our nation's biodefense response capability. For more information, visit www.jpmtmt.mil.


'/>"/>
SOURCE Joint Project Manager Transformational Medical Technologies
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. NSF awards $450,000 to UNH, Conductive Compounds Inc. for solar panel innovation
2. Grifols Awards Winners of the 9th Annual eALTA Research Fellowship at 2012 ERS Meeting
3. The Leukemia & Lymphoma Society Awards $12 Million in Research Grants in Four Critical Areas of Unmet Medical Need
4. The Masonry Heater Association of North America Announces the 2012 Masonry Heater, Bake Oven and Masonry Project Awards
5. picoSpin-45 Benchtop NMR Spectrometer a Finalist in the European Life Sciences Awards
6. San Diego Medical Director Wins Two Book Awards For Latest Medical Thriller
7. DOE-CEA Partnership Awards Mentoring Services to Finalists in National Clean Energy Business Plan Competition
8. 2012 American Business Awards?Honors SynCardia with Two Gold Stevie® Awards
9. The Scientist Magazine’s 2012 Multimedia Awards—Call for Entries
10. aTyr Pharma Receives Industry Innovation Awards from TiE and San Diego Venture Group
11. Trinity College Dublins Neuroscience and Bioengineering Programmes Receive Postgraduate Course of the Year Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... 09, 2016 , ... There’s a winning streak at Voxx Analytics: the tech ... after winning the award last year as well. Employees nominate their companies for the ... Vesely pointed to the tech company’s upbeat environment as a reason. “We don’t answer ...
(Date:12/9/2016)... ... 09, 2016 , ... Aditya Humad, Acting CFO of AxioMed and Managing Partner ... United States, Axiomed is now gaining interest from Silicon Valley. “It was satisfying to ... went on to say that, “We expect interest to continue to rise as AxioMed ...
(Date:12/9/2016)... PHILADELPHIA , Dec. 9, 2016  A ... Temple University are moving one step closer to ... orthopedic applications. OrthoMend Research, Inc., a start-up company ... acquired the exclusive license for these novel absorbable ... to develop them for commercial use. The company ...
(Date:12/9/2016)... - Portage Biotech Inc. ("Portage" or "the Company") (OTC: ... that Biohaven has issued today the following press release: ... (PRWEB) Dec 9, 2016 - Biohaven Pharmaceutical Holding Company ... U.S. Food and Drug Administration ("FDA") has granted the ... BHV-0223, an orally dissolving tablet being developed for the ...
Breaking Biology Technology:
(Date:12/6/2016)... , Dec. 6, 2016 Securus ... justice technology solutions for public safety, investigation, corrections ... jointly announced today a five (5) year funding ... agreement to expand the rehabilitation and reentry support ... PEP History Established in 2004, the Prison Entrepreneurship ...
(Date:11/30/2016)... , Nov. 30, 2016 Not many of us realize that we spend ... recovery so we need to do it well. Inadequate sleep levels have been found ... pressure, stroke, diabetes, and even cancer. Maybe now is the best time ... could help them to manage their sleep quality? Continue ... ...
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s ... ... DERMALOG is Germany's largest Multi-Biometric ... Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification System is ...
Breaking Biology News(10 mins):